ZANTAC 150: 104 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
104
Total FAERS Reports
0
Deaths Reported
0
Hospitalizations
104
As Primary/Secondary Suspect
First Report: 2004 · Latest Report: 20140620
What Are the Most Common ZANTAC 150 Side Effects?
#1 Most Reported
Off label use
32 reports (30.8%)
#2 Most Reported
Drug ineffective
21 reports (20.2%)
#3 Most Reported
Incorrect drug administration duration
15 reports (14.4%)
All ZANTAC 150 Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 32 | 30.8% | 0 | 0 |
| Drug ineffective | 21 | 20.2% | 0 | 0 |
| Incorrect drug administration duration | 15 | 14.4% | 0 | 0 |
| Intentional product misuse | 6 | 5.8% | 0 | 0 |
| Overdose | 6 | 5.8% | 0 | 0 |
| Abdominal discomfort | 5 | 4.8% | 0 | 0 |
| Abdominal distension | 5 | 4.8% | 0 | 0 |
| Abdominal pain upper | 5 | 4.8% | 0 | 0 |
| Dyspepsia | 5 | 4.8% | 0 | 0 |
| Headache | 5 | 4.8% | 0 | 0 |
| Nausea | 5 | 4.8% | 0 | 0 |
Who Reports ZANTAC 150 Side Effects? Age & Gender Data
Average age: 60.8 years. Most reports from: US. View detailed demographics →
Is ZANTAC 150 Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 2 | 0 | 0 |
| 2006 | 1 | 0 | 0 |
| 2007 | 1 | 0 | 0 |
| 2010 | 1 | 0 | 0 |
| 2012 | 2 | 0 | 0 |
| 2013 | 18 | 0 | 0 |
| 2014 | 68 | 0 | 0 |
What Is ZANTAC 150 Used For?
| Indication | Reports |
|---|---|
| Dyspepsia | 62 |
| Gastrooesophageal reflux disease | 21 |
| Product used for unknown indication | 7 |
ZANTAC 150 vs Alternatives: Which Is Safer?
ZANTAC 150 vs ZANUBRUTINIB
ZANTAC 150 vs ZAVEGEPANT
ZANTAC 150 vs ZEAXANTHIN
ZANTAC 150 vs ZELBORAF
ZANTAC 150 vs ZEMPLAR
ZANTAC 150 vs ZENATANE
ZANTAC 150 vs ZETIA
ZANTAC 150 vs ZICONOTIDE
ZANTAC 150 vs ZIDOVUDINE
ZANTAC 150 vs ZILEUTON
Official FDA Label for ZANTAC 150
Official prescribing information from the FDA-approved drug label.